Fig. 2From: Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experiencea NRS, b VAS and c number of sprays per visit (mean, median, minimum and maximum)Back to article page